Is Stryker Stock a Good Investment in 2026? SYK Fundamentals Explained

Stryker announced on 6 October 2026 that Kevin Lobo, chief executive since October 2012, will hand the job to Spencer Stiles on 1 January 2027. Lobo stays as CEO through 31 December and becomes Executive Chair; Stiles, currently President and Chief Operating Officer, succeeds him and joins a board enlarged from ten seats to eleven. The shares closed the same session at USD 278.20, down 2.46% from a USD 285.22 prior close, for a market capitalisation of about USD 106.7bn — and that is near the bottom of a 52-week range of USD 267.00 to USD 392.55.

Anyone asking whether Stryker stock is a good investment in 2026 has to separate two things the 6 October close ran together. What the numbers support is a company guiding to full-year organic net sales growth of 8.3% to 9.3% and adjusted earnings of USD 14.95 to USD 15.10 a share, with a second quarter that delivered roughly 9% organic growth and adjusted EPS of USD 3.69 — a 17.9% year-on-year increase. On the USD 278.20 close against the midpoint of that adjusted guidance, the stock trades on roughly 18.5 times forward adjusted earnings, the lowest end of its recent range. What would have to go right is the handover itself, plus the recovery from a March cyberattack that is still working its way through the comparatives, and a demonstration that the sales and EPS forecast reductions a broker flagged alongside the succession news reflect timing rather than a change in trend.

What actually happened

The mechanics are documented in Stryker's own press release and the 8-K filed with the SEC. The company entered a letter agreement with Lobo on 5 October; the announcement followed on 6 October. Lobo remains chief executive until 31 December 2026 and becomes Executive Chair from 1 January 2027. His base salary, bonus target and benefits eligibility are unchanged, but he will not receive new stock awards. Stiles becomes CEO and a director on the same date, on a USD 1.32m base salary with a 150% bonus target, plus a long-term equity award to be put forward for approval in 2027.

Both the company and the filing frame this as a planned succession rather than a surprise, and the record supports that. Stiles has spent 27 years at Stryker across Orthopaedics, MedSurg and Neurotechnology, became group president of Orthopaedics in 2019, and was promoted to President and COO effective 1 January 2026 — a year's notice, in practice, of what was coming. Lobo joined in 2011 as a group president, took the chief executive role in October 2012 and became chair in July 2014. His tenure covers more than 60 acquisitions and, latterly, the most disruptive operational event in the company's recent history.

That event matters to reading the current numbers. A cyberattack on 11 March 2026 disrupted Stryker's global Microsoft environment and shut down ordering, shipping and manufacturing for weeks; operations were not restored until the first week of April. First-quarter reported sales came in around USD 6bn, up 2.6% year on year, against growth between roughly 10% and 12% in every quarter of the prior year. Stryker's filing described a material impact on operations and on first-quarter results while maintaining full-year guidance, and it has never disclosed a dollar figure for the sales hit; one broker estimated the organic shortfall against consensus at about USD 317m.

Management called those distortions temporary, and by the second quarter they had largely normalised. Organic sales grew about 9%, adjusted EPS reached USD 3.69, and adjusted gross margin was 66.0%, up 60 basis points. The one genuine weak spot was US Vascular, where organic sales fell 6.7% on a supply disruption that created a backorder position. Full-year guidance was narrowed rather than lifted: organic growth to 8.3% to 9.3% from 8.0% to 9.5%, and adjusted EPS to USD 14.95 to USD 15.10 from USD 14.90 to USD 15.10, with foreign exchange expected to be slightly favourable at then-current rates.

Why the market reacted the way it did

A 2.46% fall is a shrug, and that is the most informative thing about it. Succession announcements the market doubts do not produce single-digit moves. This one was pre-signalled by Stiles's promotion a year earlier, hands the job to a 27-year insider, and keeps the outgoing chief executive on the board as Executive Chair, a structure designed to make continuity the default.

The more interesting point is that a meaningful share of the day's decline probably was not about the succession at all. A broker trimmed its revenue and earnings forecasts the same day while explicitly characterising the leadership transition as low-risk, attributing the reduction to management's own commentary at a September investor conference. The forecast change and the CEO news landed together and the tape could not distinguish them. For a reader trying to price the stock they are entirely different inputs: one a governance event the market has judged benign, the other a downward revision to the growth path.

The wider context is a share price that has already done considerable work. At USD 278.20 the stock sits about 29% below its 52-week high of USD 392.55 and roughly 4% above the low of USD 267.00. A derating of that size in a business still guiding to high-single-digit organic growth implies the market has repriced the multiple rather than the operating numbers — and that began well before 6 October.

The Openbook read

Momentum is weak and the succession does nothing to change it. The stock is in the bottom tenth of its 52-week range, it has given back close to a third from the high, and the only recent catalysts have been a cyberattack, a narrowed guidance range and a broker cutting forecasts. The score stays negative until the Q3 print confirms or breaks the pattern. The qualification is that momentum here is price-driven, not estimate-driven: full-year adjusted EPS guidance has moved by five cents at the bottom of the range since the start of the year.

Growth remains the strongest factor and is where the market's scepticism looks hardest to justify on the published numbers. Organic net sales growth of 8.3% to 9.3% for a company of this size is a genuinely high bar, and the second quarter delivered roughly 9% despite carrying the tail of the cyber disruption. The honest caveats are two. First, the comparative base is distorted: Q1's 2.6% reported growth means part of the recovery shows up as arithmetic rather than demand. Second, the guidance range was narrowed from the top as well as lifted from the bottom, and the September commentary that triggered the forecast cuts suggests the upper half is no longer the working assumption. Growth scores well; the direction of travel in the revision is the thing to watch.

Profitability is the cleanest factor. Adjusted gross margin of 66.0%, up 60 basis points year on year in a quarter still absorbing operational disruption, is a strong result, and adjusted EPS growth of 17.9% against roughly 9% organic sales growth shows real operating leverage. The label matters: these are adjusted figures and the GAAP numbers for the same period sit lower, so the 66% is not a reported gross margin and should not be set against a peer's reported one. Some of the quarter's EPS strength was also attributed in coverage to tariff refunds, which is not repeatable.

Solvency is not where the risk sits in this name. Stryker is a USD 106.7bn business generating high-single-digit organic growth with a 66% adjusted gross margin, and it funded more than 60 acquisitions over Lobo's tenure without the balance sheet becoming the story. The score is comfortable and the succession has no bearing on it. The cyberattack is the relevant tail risk rather than leverage: it brought lawsuits as well as lost sales, and the company declined to quantify the revenue effect.

Reward/Risk is the factor that has actually moved, and it has moved favourably on the published evidence. Roughly 18.5 times the midpoint of adjusted full-year guidance, for a company guiding to 8.3% to 9.3% organic growth with expanding adjusted gross margin, is a materially different proposition from the multiple the same guidance commanded at USD 392. The risk is that the September commentary behind the forecast cuts is the leading edge of a slower growth path, in which case the multiple is not cheap but correctly reset, and a new chief executive in his first year has every incentive to reset long-term targets rather than defend them. That is the specific asymmetry: a CEO transition is the conventional moment to rebase guidance, and the first opportunity to do it arrives within weeks of Stiles taking the chair.

The read-across

The sector point is that Stryker sets the pace in orthopaedics and MedSurg, so a handover at the top of the largest player is a sector event even when well telegraphed. Stryker's pricing discipline and the rate at which it pushes robotic platforms into hospital accounts shape what Zimmer Biomet and the ortho divisions of the diversified names can charge. A new chief executive reviewing the portfolio — including whether to keep acquiring at the pace of the last decade — changes the competitive environment for all of them, and the medtech M&A market has had Stryker as its most consistent buyer.

The starting positions across the group differ sharply. Through 2025, Zimmer Biomet fell about 14% after repeated profit warnings and was heading for a third consecutive annual decline, while Boston Scientific, Medtronic, Johnson & Johnson, Abbott, Edwards Lifesciences and GE HealthCare all finished the year higher, Boston Scientific's gains driven by repeated profit upgrades in cardiology. Jefferies went into 2026 constructive on the group, arguing tariff effects had been mitigated and policy risk was manageable. Against that backdrop, Stryker's derating looks more like a multiple problem specific to its growth premium than a read on device demand — the comparison to make on the Openbook screener rather than assuming a sector-wide downgrade.

The US Vascular weakness is worth isolating. A 6.7% organic decline driven by supply disruption and backorders is a Stryker execution issue, not a market signal, and should not be read across to peripheral vascular peers as a soft end market.

What to watch next

The hard date is Thursday 29 October 2026, when Stryker reports third-quarter results — a release at approximately 4:05pm Eastern and a webcast at 4:30pm, per the company's own 1 October announcement. Three things decide how the quarter reads. First, whether the cyber recovery the finance chief described as continuing through the back half is visible — organic growth at or above the guidance range, not flattered purely by the weak Q1 base. Second, whether the 8.3% to 9.3% organic and USD 14.95 to USD 15.10 adjusted EPS guidance holds, narrows again, or is trimmed in line with the September commentary. Third, whether US Vascular has cleared its backorder position.

Beyond October, 1 January 2027 is the governance date: Stiles becomes CEO, Lobo becomes Executive Chair, and the board moves to eleven members. What matters after that is the first full set of guidance issued under the new chief executive, and whether Stryker's long-standing framework of high-single-digit organic growth with double-digit adjusted EPS growth is reaffirmed in Stiles's own words. His long-term equity award goes forward for approval in 2027, and the performance conditions attached to it will say more about the board's medium-term expectations than any commentary.